Previous 10 | Next 10 |
DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is scheduled to participate at the Jefferies London Healthcare Conference. The present...
Commercial-stage biotech Amarin Corporation ( NASDAQ: AMRN ) gained ~13% Monday, the highest intraday gain since June, after the company said that an independent study supported the benefit of purified eicosapentaenoic acid (EPA), a component in its heart disease therapy Vas...
-- Independent RESPECT-EPA Study Now Third in a Series of Trials to Underscore CV Risk Reduction Benefits of Eicosapentaenoic Acid for Patients -- -- PROMINENT Study Failed to Show CV Risk Reduction Benefit of the Fibrate Class for Statin-Treated High-Risk Patients -- DUBL...
Summary The market is greatly overestimating the effect of higher rates and inflation on durable goods, materials and financial companies, while underestimating the impact on speculative assets. The Strategy underperformed its Russell 2000 benchmark, as positive contributions from...
Image source: The Motley Fool. Amarin (NASDAQ: AMRN) Q3 2022 Earnings Call Oct 27, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: Amarin (AMRN) Q3 2022 Earnings Call Transcript
Amarin Corp ( NASDAQ: AMRN ) posted Q3 result on Thursday that beat estimates. Q3 Non-GAAP EPS of $0.02 beats by $0.08 while revenue fell 36.7% to $89.9M, but beat estimates by $2.34M. However, the company continued to suspend 2022 revenue guidance given the un...
Amarin Corporation plc (AMRN) Q3 2022 Results Earnings Conference Call October 27, 2022, 08:00 AM ET Company Participants Lisa DeFrancesco - Senior Vice President, Corporate Affairs and Investor Relations Karim Mikhail - President and Chief Executive Officer Tom ...
The following slide deck was published by Amarin Corporation plc in conjunction with their 2022 Q3 earnings call. For further details see: Amarin Corporation plc 2022 Q3 - Results - Earnings Call Presentation
Amarin press release ( NASDAQ: AMRN ): Q3 Non-GAAP EPS of $0.02 beats by $0.08 . Revenue of $89.9M (-36.7% Y/Y) beats by $2.34M . As of September 30, 2022, Amarin reported aggregate cash and investments of $306.0M “In the third quarter of 2022, Amari...
-- U.S. Business Trends Stabilize and Progress on Operational Initiatives Result in Extended Cash Runway -- -- Commenced Launch of VAZKEPA® (icosapent ethyl) in England & Wales Mid-October As Planned – -- Obtained Positive Scientific Assessment for Reimbu...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...